New weight loss drug UBT251 enters phase 2 trial – could it be a game changer?
NCT ID NCT07395687
First seen Feb 14, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study tests a new medicine called UBT251 to see if it is safe and helps people with overweight or obesity lose weight. About 333 adults will receive either UBT251 or a placebo (dummy treatment) by chance. The main goals are to check for side effects and measure weight change over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Company, Inc
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
-
Altasciences Clinical Kansas, Inc.
RECRUITINGOverland Park, Kansas, 66212, United States
-
Altasciences Clinical LA, Inc.
RECRUITINGCypress, California, 90630, United States
Conditions
Explore the condition pages connected to this study.